gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1566Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГОВ, ГЕПАТОЛОГОВNATIONAL COLLEGE OF GASTROENTEROLOGISTS, HEPATOLOGISTSСовременные возможности применения прокинетиков в лечении гастроэзофагеальной рефлюксной болезниModern potentials of prokinetics in treatment of gastroesophageal reflux diseaseШептулинА. А.SheptulinA. A.КиприанисВ. А.KiprianisV. A.2010021120102053943Copyright © Шептулин А.А., Киприанис В.А., 20102010Шептулин А.А., Киприанис В.А.Sheptulin A.A., Kiprianis V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1566

Цель обзора. Оценить современные возможности и перспективы применения прокинетиков в лечении гастроэзофагеальной рефлюксной болезни (ГЭРБ).Основные положения. В настоящее время основными препаратами, используемыми в лечении ГЭРБ, являются ингибиторы протонной помпы (ИПП). Вместе с тем в последние годы участились случаи неэффективности их применения, что может быть обусловлено сохраняющимися «ночными кислотными прорывами», а также некислотными рефлюксами. Поскольку ГЭРБ относится к заболеваниям с первичным нарушением моторики пищевода и желудка, в ее лечении могут применяться прокинетики (домперидон, итоприда гидрохлорид)Заключение. В случаях резистентности ГЭРБ к ИПП к лечению могут быть добавлены прокинетики (итоприда гидрохлорид, домперидон).

The aim of review

The aim of review. To estimate up-to-date options and prospects of application of prokinetics in treatment of gastroesophageal reflux disease (GERD).

Original positions

Original positions. Nowadays proton pump inhibitors (PPI) are the basic drugs used in treatment of GERD. At the same time in last years cases of their inefficacy became frequent that can be caused by «night acid outbreak», and also non-acid refluxes. As GERD is diseases with primary disorders of motility of the esophagus and the stomach, in its treatment prokinetics (domperidone, itopride hydrochloride) can be applied.

Conclusion

Conclusion. In the case of resistance of GERD prokinetics can be added to PPI treatment (itopride hydrochloride, domperidone).

гастроэзофагеальная рефлюксная болезньпрокинетикиgastroesophageal reflux diseaseprokineticsReferencesИвашкин В.Т., Трухманов А.С., Шептулин А.А. и др. Диагностика и лечение гастроэзофагеальной рефлюксной болезни: Пособие для врачей. – М., 2003. – 30 с.Ивашкин В.Т., Трухманов А.С., Шептулин А.А. и др. Диагностика и лечение гастроэзофагеальной рефлюксной болезни: Пособие для врачей. – М., 2003. – 30 с.Минушкин О.Н., Лощинина Ю.Н. Эффективность применения препарата Ганатон в лечении больных ГЭРБ // Эффективная фармакотерапия в гастроэнтерологии. – 2008. – № 3. – С. 1–4.Минушкин О.Н., Лощинина Ю.Н. Эффективность применения препарата Ганатон в лечении больных ГЭРБ // Эффективная фармакотерапия в гастроэнтерологии. – 2008. – № 3. – С. 1–4.Шептулин А.А., Голочевская В.С. Прокинетики в лечении гастроэнтерологических заболеваний // Клин. фармакол. тер. – 1996. – № 1. – С. 94–96.Шептулин А.А., Голочевская В.С. Прокинетики в лечении гастроэнтерологических заболеваний // Клин. фармакол. тер. – 1996. – № 1. – С. 94–96.Шептулин А.А., Хромов В.Л. Возможности применения Координакса в лечении рефлюкс-эзофагита // Практикующий врач.– 1997. – № 10.– С. 30–31.Шептулин А.А., Хромов В.Л. Возможности применения Координакса в лечении рефлюкс-эзофагита // Практикующий врач.– 1997. – № 10.– С. 30–31.Assimakopoulos S.F., Thonopoulos K.C., Louvros E., Theocharis G. Changes in the prevalence of upper gastrointestinal tract diseases in patients referred for endoscopy during the last fifteen years // 15. UEGW. Abstracts. – Gut. – 2007. – Vol. 56 (suppl. III). – P. 202.Assimakopoulos S.F., Thonopoulos K.C., Louvros E., Theocharis G. Changes in the prevalence of upper gastrointestinal tract diseases in patients referred for endoscopy during the last fifteen years // 15. UEGW. Abstracts. – Gut. – 2007. – Vol. 56 (suppl. III). – P. 202.Becker V., Bajbouj M., Waller C. et al. Intraluminalimpedance guided therapy for PPI-resistant gastroesophageal reflux – A follow-up study // Gut. – 2007. – Vol. 56 (suppl. III). – P. 208.Becker V., Bajbouj M., Waller C. et al. Intraluminalimpedance guided therapy for PPI-resistant gastroesophageal reflux – A follow-up study // Gut. – 2007. – Vol. 56 (suppl. III). – P. 208.Blum A.L., Baldi F. and Eurocis Study Group. Effect of two dosage regimens of cisapride on relapse of reflux esophagitis, maled with an antiseсretory drug // J. Drug. Dev. – 1993. – Vol. 5 (suppl. 2). – P. 7–13.Blum A.L., Baldi F. and Eurocis Study Group. Effect of two dosage regimens of cisapride on relapse of reflux esophagitis, maled with an antiseсretory drug // J. Drug. Dev. – 1993. – Vol. 5 (suppl. 2). – P. 7–13.Boeckstaens G.E., Denison H., Ruth M. Effect of AZD3355, a novel GABA(B) agonist, on reflux and lower esophageal sphincter function in patients with GERD with symptoms despite proton pump inhibitor treatment // Gut. – 2009. – Vol. 58 (suppl. II). – P. 6.Boeckstaens G.E., Denison H., Ruth M. Effect of AZD3355, a novel GABA(B) agonist, on reflux and lower esophageal sphincter function in patients with GERD with symptoms despite proton pump inhibitor treatment // Gut. – 2009. – Vol. 58 (suppl. II). – P. 6.Brogden R., Carmine A., Heel R. et al. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as antiemetic // Drugs. – 1982. – Vol. 24. – P. 360–400.Brogden R., Carmine A., Heel R. et al. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as antiemetic // Drugs. – 1982. – Vol. 24. – P. 360–400.Casini V., Pace F., Pallotta S. et al. Usefulness of pH-impedance monitoring (pH-Mii) in a tertiary referral centre // Gut. – 2007. – Vol. 56 (suppl. III). – P. 208.Casini V., Pace F., Pallotta S. et al. Usefulness of pH-impedance monitoring (pH-Mii) in a tertiary referral centre // Gut. – 2007. – Vol. 56 (suppl. III). – P. 208.Chandrashckar T.S. Medical management of gastroesophageal reflux disease: focus on itopride // The Indian Practitioner. – 2004. – Vol. 57. – P. 725–729.Chandrashckar T.S. Medical management of gastroesophageal reflux disease: focus on itopride // The Indian Practitioner. – 2004. – Vol. 57. – P. 725–729.Dent J. Pathophysiology of GORD: a new understanding // 17 United European Gastroenterology Week. Syllabus of the Postgraduate Teaching Programme. – London, 2009. – P. 153–155.Dent J. Pathophysiology of GORD: a new understanding // 17 United European Gastroenterology Week. Syllabus of the Postgraduate Teaching Programme. – London, 2009. – P. 153–155.Galmiche J.P., Brandsaetter A., Evreux M., Hentschel E. Combined therapy with cisapride and cimetidine in severe peptic esophagitis: a double blind controlled trial // Gut. – 1988. – Vol. 29. – P. 675–681.Galmiche J.P., Brandsaetter A., Evreux M., Hentschel E. Combined therapy with cisapride and cimetidine in severe peptic esophagitis: a double blind controlled trial // Gut. – 1988. – Vol. 29. – P. 675–681.Hunt R.H., Yuan Y., Yaghhoobi M. GERD: new strategies and new failures // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 72–77.Hunt R.H., Yuan Y., Yaghhoobi M. GERD: new strategies and new failures // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 72–77.Inoue K., Sanada Y., Fijimura J., Mihara O. Clinical effect of itopride hydrochloride on the digestive symptoms of chronic gastritis with reflux esophagitis // Clin. Med. – 1999. – Vol. 15. – P. 1803–1808.Inoue K., Sanada Y., Fijimura J., Mihara O. Clinical effect of itopride hydrochloride on the digestive symptoms of chronic gastritis with reflux esophagitis // Clin. Med. – 1999. – Vol. 15. – P. 1803–1808.Janish H.D., Huttemann W., Bonzo M.H. Cisapride versus ranitidine in the treatment of reflux esophagitis // Hepatogastroenterology. – 1988. – Vol. 35. – P. 51–53.Janish H.D., Huttemann W., Bonzo M.H. Cisapride versus ranitidine in the treatment of reflux esophagitis // Hepatogastroenterology. – 1988. – Vol. 35. – P. 51–53.Kahrilas P.J. Gastroesophageal reflux disease // JAMA. – 1996. – Vol. 276. – P. 983–988.Kahrilas P.J. Gastroesophageal reflux disease // JAMA. – 1996. – Vol. 276. – P. 983–988.Kahrilas P.J., Quigley E.M., Castell D.O., Spechler T.J. The effects of tegaserod (HTF 919) on esophageal acid exposure in gastroesophageal reflux disease // Alimant. Pharmacol. Ther. – 2000. – Vol. 14. – P. 503– 509.Kahrilas P.J., Quigley E.M., Castell D.O., Spechler T.J. The effects of tegaserod (HTF 919) on esophageal acid exposure in gastroesophageal reflux disease // Alimant. Pharmacol. Ther. – 2000. – Vol. 14. – P. 503– 509.Kim Y.S., Kim T.H., Chi C.S. et al. Effect of itopride, a new prokinetiс in patients with mild GERD: a pilot study // World J. Gastroenterol. – 2005. – Vol. 11. – P. 4210–4214.Kim Y.S., Kim T.H., Chi C.S. et al. Effect of itopride, a new prokinetiс in patients with mild GERD: a pilot study // World J. Gastroenterol. – 2005. – Vol. 11. – P. 4210–4214.Lenglinger J., Eisler M. Ringhofer C. et al. Diagnostic yield of oesophageal impedance- and pH-monitoring in patients with typical symptoms of gastroesophageal reflux disease of therapy // Gut. – 2007. – Vol. 56 (suppl. III). – P. 210.Lenglinger J., Eisler M. Ringhofer C. et al. Diagnostic yield of oesophageal impedance- and pH-monitoring in patients with typical symptoms of gastroesophageal reflux disease of therapy // Gut. – 2007. – Vol. 56 (suppl. III). – P. 210.Lidiums I., Lehmann A., Checklin H. et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA agonist baclofen in normal subjects // Gastroenterology. – 2000. – Vol. 118. – P. 7–13.Lidiums I., Lehmann A., Checklin H. et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA agonist baclofen in normal subjects // Gastroenterology. – 2000. – Vol. 118. – P. 7–13.Macatula T.C., Nolasko E.R., Gloria V.I. et al. Use of baclofen in the treatment of gastroesophageal disease: a meta-analysis // Gut. – 2007. – Vol. 56 (suppl. III). – P. 216.Macatula T.C., Nolasko E.R., Gloria V.I. et al. Use of baclofen in the treatment of gastroesophageal disease: a meta-analysis // Gut. – 2007. – Vol. 56 (suppl. III). – P. 216.Mainie I., Tutuian R., Shay S. et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring // Gut. – 2006. – Vol. 55. – P. 1398–1402.Mainie I., Tutuian R., Shay S. et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring // Gut. – 2006. – Vol. 55. – P. 1398–1402.Malfertheiner P. Gastroesophageale Refluxkrankheit // Falk Gastro-Kolleg. – 2009. – N 2. – S. 21–41.Malfertheiner P. Gastroesophageale Refluxkrankheit // Falk Gastro-Kolleg. – 2009. – N 2. – S. 21–41.Peres de la Serna J., Ruiz de Leon A., Sevilla-Mantilla C. et al. Acid breakthrough in GERD patients under proton pump inhibitors (PPI) treatment in a daily practice // 15. UEGW. Abstracts. – Gut. – 2007. – Vol. 56 (suppl. III). – P. 217.Peres de la Serna J., Ruiz de Leon A., Sevilla-Mantilla C. et al. Acid breakthrough in GERD patients under proton pump inhibitors (PPI) treatment in a daily practice // 15. UEGW. Abstracts. – Gut. – 2007. – Vol. 56 (suppl. III). – P. 217.Sifirim D. Disorders of gastric emptying // Innovations in assessing gastric emptying and new pharmacology in the foregut. Workshop. – 9th World Congress OESO. – Monaco, 2008 (oral presentation).Sifirim D. Disorders of gastric emptying // Innovations in assessing gastric emptying and new pharmacology in the foregut. Workshop. – 9th World Congress OESO. – Monaco, 2008 (oral presentation).Spechler S.J. Epidemiology and natural history of gastroesophageal reflux disease // Digestion. – 1992. – Vol. 51 (suppl. 1). – P. 24–29.Spechler S.J. Epidemiology and natural history of gastroesophageal reflux disease // Digestion. – 1992. – Vol. 51 (suppl. 1). – P. 24–29.Toussaint J. Relapse prevention on esophagitis with cisapride – a multicentre placebo-controlled study // J. Drug Dev. – 1993. – Vol. 5 (suppl. 2). – P. 15–19.Toussaint J. Relapse prevention on esophagitis with cisapride – a multicentre placebo-controlled study // J. Drug Dev. – 1993. – Vol. 5 (suppl. 2). – P. 15–19.Trugdill N.J., Hussain F.N., Moustafa M. et al. The effect of cholecystokinin antagonism on postprandial lower esophageal sphincter function in asymptomatic volunteers and patients with reflux disease // Aliment. Pharmacol. Ther. – 2001. – Vol. 15. – P. 1357–1364.Trugdill N.J., Hussain F.N., Moustafa M. et al. The effect of cholecystokinin antagonism on postprandial lower esophageal sphincter function in asymptomatic volunteers and patients with reflux disease // Aliment. Pharmacol. Ther. – 2001. – Vol. 15. – P. 1357–1364.Tytgat G.N.J. Gastroesophageal reflux disease: reflection ANO 2006 // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 222–225.Tytgat G.N.J. Gastroesophageal reflux disease: reflection ANO 2006 // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 222–225.Tytgat G.N.J. Shortcomings of the first-generation proton pump inhibitors // Eur. J. Gastroenterol. Hepatol. – 2001. – Vol. 13 (suppl.). – P. 29–33.Tytgat G.N.J. Shortcomings of the first-generation proton pump inhibitors // Eur. J. Gastroenterol. Hepatol. – 2001. – Vol. 13 (suppl.). – P. 29–33.Tytgat G.N.J., Janssens J., Reynolds J.C., Wienbeck M. Update on the pathophysiology and management of gastroesophageal reflux disease: the role of prokynetic therapy // Eur. J. Gastroenterol. Hepatol. – 1996. – Vol. 8. – P. 603–611.Tytgat G.N.J., Janssens J., Reynolds J.C., Wienbeck M. Update on the pathophysiology and management of gastroesophageal reflux disease: the role of prokynetic therapy // Eur. J. Gastroenterol. Hepatol. – 1996. – Vol. 8. – P. 603–611.Vela M., Tutuian R, Katz P.O., Castell D.O. Baclofen decreases acid and non-acid postprandial gastroesophageal reflux measured by combined multichannel intraluminal impedance and pH // Aliment. Pharmacol. Ther. – 2003. – Vol. 17. – P. 243–251.Vela M., Tutuian R, Katz P.O., Castell D.O. Baclofen decreases acid and non-acid postprandial gastroesophageal reflux measured by combined multichannel intraluminal impedance and pH // Aliment. Pharmacol. Ther. – 2003. – Vol. 17. – P. 243–251.Wolfe M.M., Lowe R.C. Investing in the future of GERD // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 204–208.Wolfe M.M., Lowe R.C. Investing in the future of GERD // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 204–208.Zerbib F., Roman S., Ropert A. et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy // Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 1956–1963.Zerbib F., Roman S., Ropert A. et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy // Am. J. Gastroenterol. – 2006. – Vol. 101. – P. 1956–1963.Zhang Q., Lehmann A., Rigda R. et al. Control of transient lower esophageal sphincter relaxation and reflux by the GABA agonist baclofen in patients with gastroesophageal reflux disease // Gut. – 2002. – Vol. 50. – P. 19–24.Zhang Q., Lehmann A., Rigda R. et al. Control of transient lower esophageal sphincter relaxation and reflux by the GABA agonist baclofen in patients with gastroesophageal reflux disease // Gut. – 2002. – Vol. 50. – P. 19–24.

The authors declare that there are no conflicts of interest present.